Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,939
  • Shares Outstanding, K 50,340
  • Annual Sales, $ 17,360 K
  • Annual Income, $ -43,160 K
  • 36-Month Beta 2.96
  • Price/Sales 6.75
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +6.58%
on 12/28/17
2.20 -7.95%
on 01/10/18
-0.05 (-2.41%)
since 12/18/17
3-Month
1.55 +30.65%
on 10/19/17
2.35 -13.83%
on 12/04/17
+0.28 (+15.71%)
since 10/18/17
52-Week
1.55 +30.65%
on 10/19/17
5.75 -64.78%
on 10/11/17
-0.72 (-26.36%)
since 01/18/17

Most Recent Stories

More News
Omeros Inks Agreement With FDA for OMS721 Phase III Trial

Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

SCMP : 17.95 (-0.28%)
ACRX : 2.03 (-1.22%)
OMER : 16.72 (-2.85%)
ALXN : 120.35 (-1.45%)
Merck's Keytruda Gets Approved for Bladder Cancer in Japan

Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.

SCMP : 17.95 (-0.28%)
ACRX : 2.03 (-1.22%)
MRK : 61.13 (-1.45%)
LLY : 85.82 (-0.45%)
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up

FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.

TRVN : 1.73 (unch)
CORT : 23.58 (+6.26%)
ACRX : 2.03 (-1.22%)
MNK : 21.70 (-2.60%)
5 Reasons to Pick Emergent as an Investment-Worthy Stock

Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.

ACRX : 2.03 (-1.22%)
EBS : 49.60 (-0.46%)
GSK : 38.17 (+0.05%)
SNY : 44.51 (-0.20%)
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- GenMark Diagnostics, Lantheus, AcelRx Pharma, and Intuitive Surgical

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GNMK, LNTH, ACRX, and ISRG which can be accessed for free by signing up to www.wallstequities.com/registration....

GNMK : 4.71 (+1.07%)
LNTH : 22.60 (+0.89%)
ACRX : 2.03 (-1.22%)
ISRG : 432.07 (+0.23%)
Actinium Posts Positive DMC View on Lomab-B Phase III Trial

Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.

CORT : 23.58 (+6.26%)
ACHN : 2.95 (+1.72%)
ACRX : 2.03 (-1.22%)
ATNM : 0.71 (-2.05%)
Free Research Report as Masimo's Revenue Jumped 15.6%; EPS Surged 35%

Stock Monitor: AcelRx Pharma Post Earnings Reporting

ACRX : 2.03 (-1.22%)
MASI : 86.30 (-0.36%)
Breakfast Technical Briefing on Medical Equipment Stocks -- Intuitive Surgical, AcelRx Pharma, GenMark Diagnostics, and Lantheus

If you want a Stock Review on ISRG, ACRX, GNMK, or LNTH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com reexplores the Medical...

GNMK : 4.71 (+1.07%)
LNTH : 22.60 (+0.89%)
ACRX : 2.03 (-1.22%)
ISRG : 432.07 (+0.23%)
AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,...

ACRX : 2.03 (-1.22%)
AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company today reported third quarter 2017 financial results.

ACRX : 2.03 (-1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 2.08
1st Resistance Point 2.05
Last Price 2.03
1st Support Level 2.00
2nd Support Level 1.98

See More

52-Week High 5.75
Fibonacci 61.8% 4.15
Fibonacci 50% 3.65
Fibonacci 38.2% 3.15
Last Price 2.03
52-Week Low 1.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.